Back

UBS downgrades Ypsomed, cuts price target to 400 Swiss francs

Verifying
  • UBS downgraded Ypsomed AG to neutral and reduced its price target.
  • 400 Swiss francs is UBS's new target, down from 425 francs.
  • Novo Nordisk's REIMAGINE-4 trial found Cagrisema non-inferior for weight loss, but not HbA1c.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
UBS downgrades Ypsomed, cuts price target to 400 Swiss francs - CoinPost Terminal